Clinical trial
Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell…
NCT00209014 · Emory University, Other · Terminated
Key facts
| NCT number | NCT00209014 |
|---|---|
| Title | Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease |
| Official title | Phase II Trial of Thalidomide in Refractory/Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin's Disease |
| Lead sponsor | Emory University, Other |
| Collaborators | Celgene Corporation Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | B-Cell Lymphoma, Hodgkin's Disease |
| Intervention type | Drug |
| Interventions | Thalidomide |
| Enrollment | 2 |
| Start date | Jul 1, 2003 |
| Completion | Jun 1, 2006 |
| First posted | Sep 21, 2005 |
| Last update posted | May 7, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: